MODIFICATION
65 -- 200 mg and 100 mg of specific peptides
- Notice Date
- 12/11/2009
- Notice Type
- Modification/Amendment
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100021-KM
- Archive Date
- 1/7/2010
- Point of Contact
- Karri L. Mares, Phone: 3014357774, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
maresk@mail.nih.gov, cr214i@nih.gov
(maresk@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Center for Cancer Research (CCR), plans to procure on a sole source basis 200 mg each of the following peptides: HIV gp120 242-261, HIV gp120 482-497, SIV Gag 260-274, SIV Rev, SIV Gag 260-264-p11c, Gag 260-274-Tat 28-35, PCLUS3-CL10 (HIV-env+SIVGag181), PCLUS6.1-CL10 (Hiv-env+SIVGag181), PCLUS3-Pol143 (HIV-env+SIVPol143), PCLUS3-Gag372 (HIV-env+SIVGag372), PCLUS3-Tat2 (HIV-env+HIVTat2), PCLUS3-Tat3 (HIV-env+HIVTat3), PLCUS3-Vif (HIV-env+SIV-Vif), PLCUS3-Gag (HIV-env+SIVgag178-186), PLCUS3-POL(HIV-env+SIVPOL507-517), PLCUS3-Gag (HIV-env+SIVgag71-79), PLCUS3-Nef((HIV-env+SIVNef159-167), PLCUS3- Nef (HIV-env+SIVNef 169-177), PLCUS3- Vif (HIV-env+SIV-Vif 97-104), PLCUS3-Pol (HIV-env+SIV pol 324-332); and 100 mg each of the following peptides: HIV gp120 242-261, HIV gp120 482-497, SIV Gag 260-274, SIV Rev, SIV Gag 260-264-p11c-CTL, Gag 260-274-Tat 28-35-CTL, PCLUS3-CL10 (HIV-env+SIVGag181)-helper, PCLUS6.1-CL10 (Hiv-env+SIVGag181)-Helper, PCLUS3-Pol143 (HIV-env+SIVPol143)-CTL, PCLUS3-Gag372 (HIV-env+SIVGag372)-CTL, PCLUS3-Tat2 (HIV-env+HIVTat2)-CTL, PCLUS3-Tat3 (HIV-env+HIVTat3)-CTL, PLCUS3-Vif (HIV-env+SIVVif)-CTL, Nef 159-167, Gag71-79, Nef 169-177, Vif 97-104, Pol 324-332, Gag 178-186, Pol 507-517 from PolyPeptide Laboratories; 9395 Cabot Drive; San Diego, CA 92126. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Delivery shall be 45 days from date of award. The purpose of this purchase is to acquire the same peptides used in previous studies to continue research to develop vaccines against cancer and HIV. The Center for Cancer Research has a requirement for peptides to 1) immunize macaques; and 2) to perform immune assays to evaluate HIV vaccine efficacy. The peptides the NCI used for previous macaque studies were all from PolyPeptide Laboratories. For some of the peptides, PolyPeptide has remaining material from the same batch which they sent us previously. If the peptides come from a different source, the NCI will not be able to compare the results directly with those from animals immunized previously with the same peptides obtained from PolyPeptide Laboratores. To maintain continuity of the research from one study to the next, the NCI needs to order the same peptides from the same company. PolyPeptide Laboratories is the only known vendor, to the NCI, who can provide these required peptides. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office on or before 11:00 AM EST on December 23, 2009. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions at the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Karri Mares, Contract Specialist at maresk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-­­­­­100021-KM on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100021-KM /listing.html)
- Record
- SN02022198-W 20091213/091211235231-749e9e94872f6869a182b05e21b134cf (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |